Overview

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

Status:
Completed
Trial end date:
2016-12-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and tolerability of a single dose of MEDI8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of MEDI8852 alone in adult participants with acute, uncomplicated influenza caused by Type A strains.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
MedImmune LLC
Treatments:
MEDI8852
Oseltamivir